Glatiramer acetate is a synthetic polypeptide
similar to myelin basic protein. It is thought to work
by provoking the immune system to shift to a less
inflammatory response. In several clinical trials, glatiramer
acetate has shown a favorable effect on relapses and
MRI outcomes. An open-label extension of the original
phase 3 trial is ongoing and has established the
long-term safety of glatiramer acetate (Ford et al., 2010)